Pharmabiz1mon
MJFF launches initiative to expedite development of LRRK2-targeted therapies and biomarkers for Parkinson’s disease
The Michael J. Fox Foundation (MJFF) has launched a major initiative to rapidly expedite development of therapeutic strategies targeting LRRK2. Called the LRRK2 Investigative Therapeutics Exchange ...
FierceBiotech6d
Novartis pays Schrödinger $150M, bets billions on the back end to form drug discovery pact
Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...
SandboxAQ Partners with The Michael J. Fox Foundation for Parkinson's Research in $25 Million Initiative to Develop Novel Treatments
SandboxAQ announced today it has signed a $25 million research grant through The Michael J. Fox Foundation for Parkinson's Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program to ...
Business Insider27d
Promising Advancements in CNS and Oncology Portfolios Drive Buy Rating for Arvinas
Akash Tewari’s rating is based on Arvinas Holding Company’s promising advancements in their central nervous system (CNS) portfolio, particularly with their LRRK2 degrader, ARV-102, which is ...
TMCnet19d
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
TACTIVE-K: Phase 1/2 clinical trial with vepdegestrant plus Pfizer’s novel CDK4 inhibitor atirmociclib (ClinicalTrials.gov Identifier: NCT06206837) ARV-102: Oral PROTAC LRRK2 degrader In October, ...